|
|
|
|
| LEADER |
02803nam a2200505Ia 4500 |
| 001 |
10.1016-j.plabm.2021.e00207 |
| 008 |
220427s2021 CNT 000 0 und d |
| 020 |
|
|
|a 23525517 (ISSN)
|
| 245 |
1 |
0 |
|a Low levels of spexin and adiponectin may predict insulin resistance in patients with non-alcoholic fatty liver
|
| 260 |
|
0 |
|b Elsevier B.V.
|c 2021
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.plabm.2021.e00207
|
| 520 |
3 |
|
|a Adipose tissue is endocrine organ that responds by secreting numerous hormones that regulate metabolism in skeletal muscle and the liver. The aim of this study was to compare the levels of spexin and adiponectin in patients with non-alcoholic fatty liver and evaluate the relationship between circulating adipocytokines and insulin resistance. Two groups of subjects were evaluated: 41 non-alcoholic fatty liver subjects (age 35.17 ± 12.29 year, BMI 30.97 ± 2.75 kg/m2) and 38 normal controls (age 38.47 ± 11.63 year, BMI 22.83 ± 3.00 kg/m2). Plasma concentrations of spexin and adiponectin were determined using immunosorbent assay kits. Insulin resistance was assessed using the homeostasis model assessment (HOMA-IR) formula derived from fasting insulin and glucose levels. Compared to normal controls, plasma concentrations of spexin and adiponectin were significantly lower in patients with non-alcoholic fatty liver (P < 0.001). Spexin did not correlate with BMI but did significantly correlate with HOMA-IR (r = -0.368; P = 0.018) and adiponectin (r = 0.378; P = 0.043), and this correlation remained significant after adjustment for gender and BMI. In this small group of patients with non-alcoholic fatty liver we demonstrated that insulin resistance correlated strongly with spexin and adiponectin levels. © 2021 The Authors
|
| 650 |
0 |
4 |
|a adiponectin
|
| 650 |
0 |
4 |
|a Adiponectin
|
| 650 |
0 |
4 |
|a adult
|
| 650 |
0 |
4 |
|a Article
|
| 650 |
0 |
4 |
|a body mass
|
| 650 |
0 |
4 |
|a clinical article
|
| 650 |
0 |
4 |
|a controlled study
|
| 650 |
0 |
4 |
|a cytokine
|
| 650 |
0 |
4 |
|a fasting
|
| 650 |
0 |
4 |
|a female
|
| 650 |
0 |
4 |
|a gender
|
| 650 |
0 |
4 |
|a glucose
|
| 650 |
0 |
4 |
|a glucose blood level
|
| 650 |
0 |
4 |
|a homeostasis model assessment
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a immunoadsorption
|
| 650 |
0 |
4 |
|a insulin
|
| 650 |
0 |
4 |
|a insulin blood level
|
| 650 |
0 |
4 |
|a insulin resistance
|
| 650 |
0 |
4 |
|a Insulin resistance
|
| 650 |
0 |
4 |
|a male
|
| 650 |
0 |
4 |
|a NAFLD
|
| 650 |
0 |
4 |
|a nonalcoholic fatty liver
|
| 650 |
0 |
4 |
|a pathogenesis
|
| 650 |
0 |
4 |
|a protein blood level
|
| 650 |
0 |
4 |
|a spexin
|
| 650 |
0 |
4 |
|a Spexin
|
| 650 |
0 |
4 |
|a unclassified drug
|
| 700 |
1 |
|
|a Li, G.
|e author
|
| 700 |
1 |
|
|a She, Y.
|e author
|
| 700 |
1 |
|
|a Zhang, L.
|e author
|
| 700 |
1 |
|
|a Zhang, Z.
|e author
|
| 773 |
|
|
|t Practical Laboratory Medicine
|
